REGN FY 2016 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4.9B+18.4% YoY

Gross Profit

$4.5B91.7% margin

Operating Income

$1.3B27.4% margin

Net Income

$896M18.4% margin

EPS (Diluted)

$7.70

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$974M

Stock-Based Comp.

$560M

Balance Sheet

Total Assets

$7.0B

Total Liabilities

$2.5B

Stockholders' Equity

$4.4B

Cash & Equivalents

$535M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.9B	$4.1B	+18.4%
Gross Profit	$4.5B	$3.6B	+22.5%
Operating Income	$1.3B	$1.3B	+6.3%
Net Income	$896M	$636M	+40.8%